Kiora Pharmaceuticals, Inc. (KPRX) Earnings History
Annual and quarterly earnings data from 2012 to 2024
Loading earnings history...
KPRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
KPRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | 28.2% | 22.5% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | -27038.7% | -56960.5% | -56901.7% |
Download Data
Export KPRX earnings history in CSV or JSON format
Free sign-in required to download data
Kiora Pharmaceuticals, Inc. (KPRX) Earnings Overview
As of May 8, 2026, Kiora Pharmaceuticals, Inc. (KPRX) reported trailing twelve-month net income of -$9M, reflecting +103.6% year-over-year growth. The company earned $-1.96 per diluted share over the past four quarters, with a net profit margin of 22.5%.
Looking at the long-term picture, KPRX's historical earnings data spans multiple years. The company achieved its highest annual net income of $4M in fiscal 2024, representing a new all-time high.
Kiora Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including OCUL (-$290M net income, -513.2% margin), LENZ (-$82M net income, -430.3% margin), NUVL (-$450M net income), KPRX has outperformed on profitability metrics. Compare KPRX vs OCUL →
KPRX Earnings vs Peers
Earnings metrics vs comparable public companies
KPRX Historical Earnings Data (2012–2024)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $4M | +128.7% | $5M | $0.87 | 22.5% | 28.2% |
| 2023 | -$13M | +7.9% | -$13M | $-24.25 | - | - |
| 2022 | -$14M | +1.4% | -$12M | $-18.55 | - | - |
| 2021 | -$14M | -100.7% | -$14M | $-68.00 | - | - |
| 2020 | -$7M | +3.3% | -$7M | $-70.50 | -56901.7% | -56960.5% |
| 2019 | -$7M | +34.4% | -$7M | $-89.24 | -264.2% | -260.6% |
| 2018 | -$11M | +18.2% | -$11M | $-182.81 | -654.2% | -656.3% |
| 2017 | -$13M | +0.9% | -$15M | $-556.17 | -3243.5% | -3572.7% |
| 2016 | -$13M | -59.0% | -$13M | $-906.30 | -1993.8% | -1994.3% |
| 2015 | -$8M | -373.1% | -$7M | $-817.01 | - | - |
See KPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KPRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KPRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKPRX — Frequently Asked Questions
Quick answers to the most common questions about buying KPRX stock.
Is KPRX growing earnings?
KPRX EPS is $-1.96, with earnings growth accelerating to +103.6%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-9M.
What are KPRX's profit margins?
Kiora Pharmaceuticals, Inc. net margin is +22.5%, with operating margin at +28.2%. Above-average margins indicate pricing power.
How consistent are KPRX's earnings?
KPRX earnings data spans 2012-2024. The accelerating earnings trend is +103.6% YoY. Historical data enables comparison across business cycles.